Baseline characteristics of patients with DLBCL with and without SCNSL
| Variables . | Patients with SCNSL (N = 68) . | Patients without SCNSL (N = 1904) . | P value . |
|---|---|---|---|
| Age, median (IQR), y | 71.2 (65-77) | 69.5 (59-76) | .28 |
| Age >60, n (%) | |||
| Yes | 53 (77.9) | 1404 (73.7) | .49 |
| No | 15 (22.1) | 500 (26.2) | |
| Sex, n (%) | |||
| Female | 20 (29.4) | 799 (42) | .045 |
| Male | 48 (70.6) | 1105 (58) | |
| ECOG PS, n (%) | |||
| 0-1 | 44 (64.7) | 1636 (85.9) | <.001 |
| >1 | 24 (35.3) | 268 (14.1) | |
| EN sites, n (%) | |||
| 0 | 6 (8.8) | 672 (35.3) | <.001 |
| 1 | 24 (35.3) | 673 (35.5) | |
| 2 | 17 (25) | 298 (15.6) | |
| >2 | 21 (30.9) | 261 (13.7) | |
| Stage, n (%) | |||
| I-II | 13 (19.1) | 686 (36.0) | .004 |
| III-IV | 55 (80.9) | 1218 (64.0) | |
| LDH,∗ n (%) | |||
| Normal | 17 (25.0) | 889 (47.4) | <.001 |
| Elevated | 51 (75.0) | 985 (52.6) | |
| CNS-IPI, n (%) | |||
| 0-1 | 11 (16.2) | 547 (28.7) | <.001 |
| 2-3 | 20 (29.4) | 969 (50.9) | |
| 4-6 | 37 (54.4) | 388 (30.4) | |
| First-line treatment, n (%) | |||
| R-CHOP or similar (supplemental Table 1) | 67 (98.5) | 1884 (98.9) | .19 |
| Other regimens | 1 (1.5) | 20 (1.1) | |
| Response group, n (%) | |||
| CR | 32 (47.1) | 1515 (79.6) | <.001 |
| Non-CR | 36 (52.9) | 389 (20.4) | |
| CNS prophylaxis, HD-MTX, n (%) | <.001 | ||
| Yes | 29 (42.6) | 368 (19.3) | |
| No† | 39 (57.4) | 1536 (80.7) | |
| Cycles of HD-MTX,‡ median (IQR) | 2.0 (2-2) | 2.0 (2-2) | .22 |
| CNS prophylaxis, HD-MTX, CNS-IPI 4-6, n (%) | .031 | ||
| Yes | 20 (54) | 135 (34.7) | |
| No | 17 (46) | 253 (65.2) |
| Variables . | Patients with SCNSL (N = 68) . | Patients without SCNSL (N = 1904) . | P value . |
|---|---|---|---|
| Age, median (IQR), y | 71.2 (65-77) | 69.5 (59-76) | .28 |
| Age >60, n (%) | |||
| Yes | 53 (77.9) | 1404 (73.7) | .49 |
| No | 15 (22.1) | 500 (26.2) | |
| Sex, n (%) | |||
| Female | 20 (29.4) | 799 (42) | .045 |
| Male | 48 (70.6) | 1105 (58) | |
| ECOG PS, n (%) | |||
| 0-1 | 44 (64.7) | 1636 (85.9) | <.001 |
| >1 | 24 (35.3) | 268 (14.1) | |
| EN sites, n (%) | |||
| 0 | 6 (8.8) | 672 (35.3) | <.001 |
| 1 | 24 (35.3) | 673 (35.5) | |
| 2 | 17 (25) | 298 (15.6) | |
| >2 | 21 (30.9) | 261 (13.7) | |
| Stage, n (%) | |||
| I-II | 13 (19.1) | 686 (36.0) | .004 |
| III-IV | 55 (80.9) | 1218 (64.0) | |
| LDH,∗ n (%) | |||
| Normal | 17 (25.0) | 889 (47.4) | <.001 |
| Elevated | 51 (75.0) | 985 (52.6) | |
| CNS-IPI, n (%) | |||
| 0-1 | 11 (16.2) | 547 (28.7) | <.001 |
| 2-3 | 20 (29.4) | 969 (50.9) | |
| 4-6 | 37 (54.4) | 388 (30.4) | |
| First-line treatment, n (%) | |||
| R-CHOP or similar (supplemental Table 1) | 67 (98.5) | 1884 (98.9) | .19 |
| Other regimens | 1 (1.5) | 20 (1.1) | |
| Response group, n (%) | |||
| CR | 32 (47.1) | 1515 (79.6) | <.001 |
| Non-CR | 36 (52.9) | 389 (20.4) | |
| CNS prophylaxis, HD-MTX, n (%) | <.001 | ||
| Yes | 29 (42.6) | 368 (19.3) | |
| No† | 39 (57.4) | 1536 (80.7) | |
| Cycles of HD-MTX,‡ median (IQR) | 2.0 (2-2) | 2.0 (2-2) | .22 |
| CNS prophylaxis, HD-MTX, CNS-IPI 4-6, n (%) | .031 | ||
| Yes | 20 (54) | 135 (34.7) | |
| No | 17 (46) | 253 (65.2) |
Boldface values represent statistically significant results.
ECOG, Eastern Cooperative Oncology Group.
Missing values in 30 patients in the group of patients without SCNSL.
High-dose cytarabine (HD-AraC) was administered to 4 patients in the group of patients without SCNSL.
Missing values in 6 patients in the group of patients without SCNSL.